Moderna Inc

• FDA granted accelerated approval for Ultomiris to treat primary IgA nephropathy. • AstraZeneca reports annual revenue of $58.74B and net profit of $10.22B. • Analysts issued Buy ratings with an average price target of $210.32.

• Merck shares faced downward pressure from profit-taking and prominent analyst downgrades. • Investors expressed concern over upcoming quarterly earnings and Keytruda patent expiration. • Annual revenue reached $65.01B with a net profit of $18.25B.

• Johnson and Johnson shares advanced following positive clinical trial data in electrophysiology. • Management raised full-year sales and adjusted earnings guidance amid solid third-quarter performance. • Institutional capital rotated into the healthcare leader, supported by strong dividend history.

• Analysts raised Eli Lilly targets ahead of third-quarter earnings. • Strong demand for Mounjaro and Zepbound drove momentum. • Capital investments expanded manufacturing facilities globally.

• Moderna shares rose ahead of late-stage clinical trial results for intismeran autogene. • The companies are preparing regulatory submissions for United States Food and Drug Administration approval. • Moderna reported an annual revenue of $1.94 billion and a net loss.

• Revolution Medicines initiated patient treatment in new global Phase 3 clinical trials. • Analysts published bullish notes and raised price targets for the company. • The company reported zero annual revenue and a net loss of $1.13B.